BII, DPI & EBRD’s investment into KELIX bio’s operations in Egypt and Morocco

Lead party: British International Investment (BII) (investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco, Egypt Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity · Equity stake: 1% ·…


Lead party: British International Investment (BII) (investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: KELIX Bio Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco, Egypt

Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Equity · Equity stake: 1% · Fund: African Development Partners III (ADP III)

Investors/buyers: British International Investment (BII), Development Partners International (DPI), European Bank for Reconstruction and Development (EBRD)

Legal advisers: not identified in the source record.

Source: announced 1 November 2020. Original announcement: bii.co.uk.